Published in Hepatitis Weekly, February 11th, 2002
Cases of life-threatening hepatic failure resulting in transplantations or deaths have been reported in patients treated with Serzone at a rate of 1 case per 250,000 to 300,000 patient-years of Serzone treatment. The U.S. Food and Drug Administration (FDA) has advised that treatment with Serzone should not be initiated in individuals with active liver disease or with elevated baseline serum transaminases. Patients who develop evidence of hepatocellular injury, such...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.